1. Academic Validation
  2. Characterization of Aminobenzylphenols as Protein Disulfide Isomerase Inhibitors in Glioblastoma Cell Lines

Characterization of Aminobenzylphenols as Protein Disulfide Isomerase Inhibitors in Glioblastoma Cell Lines

  • J Med Chem. 2020 Sep 24;63(18):10263-10286. doi: 10.1021/acs.jmedchem.0c00728.
Andrea Shergalis 1 Ding Xue 1 Fatma Z Gharbia 1 Hannah Driks 1 Binita Shrestha 1 Amina Tanweer 1 Kirin Cromer 1 Mats Ljungman 2 Nouri Neamati 1
Affiliations

Affiliations

  • 1 Department of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States.
  • 2 Department of Radiation Oncology, University of Michigan Medical School and Rogel Cancer Center, School of Public Health, Ann Arbor, Michigan 48109, United States.
Abstract

Disulfide bond formation is a critical post-translational modification of newly synthesized polypeptides in the oxidizing environment of the endoplasmic reticulum and is mediated by protein disulfide isomerase (PDIA1). In this study, we report a series of α-aminobenzylphenol analogues as potent PDI inhibitors. The lead compound, AS15, is a covalent nanomolar inhibitor of PDI, and the combination of AS15 analogues with glutathione synthesis inhibitor buthionine sulfoximine (BSO) leads to synergistic cell growth inhibition. Using nascent RNA Sequencing, we show that an AS15 analogue triggers the unfolded protein response in glioblastoma cells. A BODIPY-labeled analogue binds proteins including PDIA1, suggesting that the compounds are cell-permeable and reach the intended target. Taken together, these findings demonstrate an extensive biochemical characterization of a novel series of highly potent reactive small molecules that covalently bind to PDI.

Figures